No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine
Paul V Licciardi, Zheng Quan Toh, Elizabeth A Clutterbuck, Anne Balloch, Rachel A Marimla, Leena Tikkanen, Karen E Lamb, Kathryn J Bright, Uraia Rabuatoka, Lisi Tikoduadua, Laura K Boelsen, Eileen M Dunne, Catherine Satzke, Yin Bun Cheung, Andrew J Pollard, Fiona M Russell, Edward K Mulholland
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | MOSBY-ELSEVIER | Published : 2016
BACKGROUND: A randomized controlled trial in Fiji examined the immunogenicity and effect on nasopharyngeal carriage after 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax) at 12 months of age. At 18 months of age, children given 23vPPV exhibited immune hyporesponsiveness to a micro-23vPPV (20%) challenge dose in terms of serotype-specific IgG and opsonophagocytosis, while 23vPPV had no effect on vaccine-type carriage. OBJECTIVE: This follow-up study examined the long-term effect of the 12-month 23vPPV dose by evaluating the immune response to 13-valent pneumococcal conjugate ..View full abstract
Awarded by National Institutes of Allergy and Infectious Disease grant
Awarded by National Research Foundation, Singapore under its Clinician Scientist Award
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Supported by a National Institutes of Allergy and Infectious Disease grant (1R01AI085198-01A1). P.V.L. is a recipient of an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship. Y.B.C. was supported by the National Research Foundation, Singapore, under its Clinician Scientist Award (award no. NMRC/CSA/039/2011) administered by the Singapore Ministry of Health's National Medical Research Council. E.A.C. was supported by the NIHR Oxford Biomedical Research Centre. A.J.P. is a Jenner Institute Investigator and a James Martin Senior Fellow. We also acknowledge the support of the Victorian Government's Operational Infrastructure Support Program. The views expressed in this manuscript do not necessarily reflect the views of the UK Department of Health or Joint Committee on Vaccination and Immunisation.